Mucosal Melanoma: An Overview of Recent Therapies.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: mucosal melanoma
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Other advances, particularly through the exploration of novel and combination therapies, are a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.
Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma in risk factors, prognosis, and treatment.
APA
Griffin Z, Mattei J (2026). Mucosal Melanoma: An Overview of Recent Therapies.. Current pharmaceutical design, 32(4), 267-275. https://doi.org/10.2174/0113816128340751241220045149
MLA
Griffin Z, et al.. "Mucosal Melanoma: An Overview of Recent Therapies.." Current pharmaceutical design, vol. 32, no. 4, 2026, pp. 267-275.
PMID
39757680 ↗
Abstract 한글 요약
Mucosal Melanoma (MM) is an aggressive disease that is distinct from cutaneous melanoma in risk factors, prognosis, and treatment. Surgical treatment is currently the treatment of choice for localized disease; however, the recurrence rate is common. For advanced or metastatic disease, immunotherapy with PD-1 inhibitors and anti-CTLA is generally first-line treatment, however the overall responses to immunotherapy in MM are often lower and less robust when compared to that observed in cutaneous melanoma. Adoptive-TIL therapy has shown great promise. Other advances, particularly through the exploration of novel and combination therapies, are a step forward and a hope to improve outcomes in patients with mucosal melanoma. In this review, we summarize current treatment options for MM, and we updated future clinical trials available for this population of patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.